Now, the Florida-based drugmaker has parried another Firdapse challenger in Teva Pharmaceuticals, which had hoped to market a generic version of the Lambert-Eaton myasthenic syndrome (LEMS ...

Additionally, Teva’s efforts to address medium-term portfolio challenges, including the potential revenue impacts from the expiration of the generic settlement and the upcoming Drug Price ...

Pharmaceutical companies brace for the upcoming Trump administration. Teva Pharmaceuticals (TEVA ... year because we're the largest supplier of generic medicines to the US. I think one in 10 ...

Watch the video above to hear more about Teva's generic obesity drug advancements and the CEO's expectations about merger and acquisition (M&A) activity. To watch more expert insights and analysis ...

This Agreement resolves the patent litigation brought by Catalyst and its licensor SERB S.A in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic ...

Teva cannot market its generic ... SERB S.A in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Firdapse (amifampridine) 10 mg tablets ...

has reached a Settlement Agreement with Teva Pharmaceuticals regarding patent litigation over the generic version of FIRDAPSE® (amifampridine) 10 mg tablets. Under this agreement, Teva is ...

The U.S. Federal Trade Commission, which has warned pharmaceutical companies against submitting irrelevant patents to the FDA to limit generic competition, supported Amneal's lawsuit. A Teva ...

Teva Pharmaceutical (NYSE:TEVA) shares rose for seven straight sessions, as the stock closed about 1% higher at $22.42 on Tuesday. The Israeli drugmaker stock added 34.5% in the preceding six ...